Mavacamten plus ablation for symptomatic hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial combines a new heart medication (mavacamten) with a procedure called radiofrequency ablation to treat a condition where the heart muscle thickens and blocks blood flow. It is for people who still have symptoms despite standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and weigh more than 99 pounds (45 kg).
- You have a type of thickened heart muscle that blocks blood flow (obstructive hypertrophic cardiomyopathy) with a specific heart pressure reading of 50 mm Hg or higher at rest or with a valsalva maneuver.
- Your heart's pumping function (ejection fraction) is 55% or higher.
- You have symptoms like shortness of breath or chest pain that limit your activity (NYHA class II or III) and your oxygen level at rest is at least 90%.
- You have not taken certain heart medications (like disopyramide, cibenzoline, or ranolazine) in the last 14 days, and you are not on a combination of beta-blockers with verapamil or diltiazem.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study checks how safe the drug mavacamten is for Korean patients with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM). It is for people who are already prescribed the drug by their doctor.
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
Hear when a new Obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.